アジア太平洋地域の細胞治療・遺伝子治療市場：2020年

当レポートでは、アジア太平洋地域の細胞治療・遺伝子治療市場について調査分析し、製品パイプライン、将来の拡張計画、使用技術、生産能力、温度要件、製造能力、SCMの選好などについて、体系的な情報を提供しています。

目次

第1章 イントロダクション

• 序文
• 調査範囲とデータ範囲
• IMAPACの調査手法

第2章 企業別の分析

• 企業概要
• GMP認定
• 施設の規模、設備、能力など
• 拡張計画
• 現在の製品パイプライン
• 開発段階
• 生産能力
• プラットフォーム技術
• 製品の温度要件
• 提供とSCMの選好
• パートナーシップ・提携
• 財務実績
• 企業ハイライト、ニュース、アップデート
• インタビュー

第3章 地域別のデータと分析 (中国、台湾、日本、韓国、インド、オーストラリアなど)

• 細胞治療・遺伝子治療企業の分布
• 標的となる疾患の種類
• 臨床試験のフェーズ段階
• 同種異系 vs. 自家療法
• 標的抗原

第4章 その他のレポート

• 参考文献
• 免責事項
• 出版社について
• その他のレポート

List of Tables and figures

REGIONS COVERED IN ASIA PACIFIC

• FIGURE 1: TOP 60 CELL AND GENE THERAPY KEY PLAYERS FROM ASIA PACIFIC REGIONS

CHINA

• FIGURE 2: STAGE OF DEVELOPMENT OF CELL THERAPY IN GREATER CHINA
• FIGURE 3: REGULATORY APPROVAL IN THE REGION
• FIGURE 4: COMPANY BASED PIPELINE ANALYSIS IN THE REGION
• FIGURE 5: NUMBER OF KEY PLAYERS ANALYSIS IN THE REGION JAPAN
• FIGURE 6: STAGE OF DEVELOPMENT OF CELL THERAPY IN THE REGION
• FIGURE 7: REGULATORY APPROVAL IN THE REGION
• FIGURE 8: COMPANY BASED PIPELINE ANALYSIS IN THE REGION
• FIGURE 9: NUMBER OF KEY PLAYERS ANALYSIS IN THE REGION

KOREA

• FIGURE 10: STAGE OF DEVELOPMENT OF CELL THERAPY IN THE REGION
• FIGURE 11: REGULATORY APPROVAL IN THE REGION
• FIGURE 12: COMPANY BASED PIPELINE ANALYSIS IN THE REGION
• FIGURE 13: NUMBER OF KEY PLAYERS ANALYSIS IN THE REGION

TAIWAN

• FIGURE 14: STAGE OF DEVELOPMENT OF CELL THERAPY IN THE REGION
• FIGURE 15: REGULATORY APPROVAL IN THE REGION
• FIGURE 16: COMPANY BASED PIPELINE ANALYSIS IN THE REGION
• FIGURE 17: NUMBER OF KEY PLAYERS ANALYSIS IN THE REGION

AUSTRALIA & SEA

• FIGURE 18: STAGE OF DEVELOPMENT OF CELL THERAPY IN THE REGION
• FIGURE 19: REGULATORY APPROVAL IN THE REGION
• FIGURE 20: COMPANY BASED PIPELINE ANALYSIS IN THE REGION
• FIGURE 21: NUMBER OF KEY PLAYERS ANALYSIS IN THE REGION

‘APAC Cell & Gene Therapy Market 2020’ covers comprehensive information on parameters such as product pipeline, future expansion plans, technologies used, production capacity, temperature requirements, manufacturing capabilities, and SCM preferences. It also contains analysis on market growth, M&As, financial updates, upcoming facilities and more!

It provides readers a closer look into companies such as Chugai, Tessa Therapeutics, Daewong Pharm, Eutilex, Carmine Therapeutics, Sumitomo Dainippon, Unicocell Biomed, JW Creagene, Takara Bio and more!

Table of Contents

Section 1

• Preface
• Report Scope & Data Coverage
• IMAPAC's Research Methodology

Section 2 - Company-Wise Analysis

• Company Overview
• GMP Certifications
• Facilities' Size, Equipment, Capabilities etc.
• Expansion Plans
• Current Product Pipeline
• Stage of Development
• Production Capacity
• Platform Technologies
• Product Temperature Requirements
• Preferred Delivery and SCM methods
• Partnerships & Collaborations
• Financial Performance
• Company Highlights, News & Updates
• Interviews

Section 3: Region-Wise Data & Analysis {Regions Covered: China, Taiwan, Japan& Korea, India, Australia & Sea}

• Distribution of Cell & Gene Therapy Companies
• Targeted Disease Types
• Stage of clinical trial phase
• Allogenic vs Autolog0us Therapies
• Targeted Antigens

Section 4: Our Other Reports

• Bibiliography
• Disclaimer
• About Us
• Our Other Reports